{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:09:44Z","timestamp":1790856584247,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-026-06619-2","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:14:13Z","timestamp":1789812853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic challenges in primary aldosteronism evaluation and finerenone use"],"prefix":"10.1186","volume":"20","author":[{"given":"Yuwan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuairan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sancong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"6619_CR1","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","volume":"110","author":"GK Adler","year":"2025","unstructured":"Adler GK, Stowasser M, Correa RR, et al. Primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2025;110:2453\u201395. https:\/\/doi.org\/10.1210\/clinem\/dgaf284.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"6619_CR2","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1080\/10641960802443282","volume":"30","author":"S Niizuma","year":"2008","unstructured":"Niizuma S, Nakahama H, Kamide K, et al. The cutoff value of aldosterone-to-renin ratio for the diagnosis of primary aldosteronism in patients taking antihypertensive medicine. Clin Exp Hypertens. 2008;30(7):640\u20137. https:\/\/doi.org\/10.1080\/10641960802443282.","journal-title":"Clin Exp Hypertens"},{"key":"6619_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"Monticone S, D\u2019Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6:41\u201350. https:\/\/doi.org\/10.1016\/S2213-8587(17)30319-4.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6619_CR4","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912\u20134018. https:\/\/doi.org\/10.1093\/eurheartj\/ehae178.","journal-title":"Eur Heart J"},{"key":"6619_CR5","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.125.25855","volume":"83","author":"AJ Newman","year":"2026","unstructured":"Newman AJ, Tsai LC, Abel EE, et al. Impact of age, sex, and race on primary aldosteronism test interpretations. Hypertension. 2026;83: e25855. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.125.25855.","journal-title":"Hypertension"},{"key":"6619_CR6","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","volume":"60","author":"X Jeunemaitre","year":"1987","unstructured":"Jeunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60:820\u20135. https:\/\/doi.org\/10.1016\/0002-9149(87)91030-7.","journal-title":"Am J Cardiol"},{"key":"6619_CR7","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1080\/13543784.2021.2002844","volume":"30","author":"J Barrera-Chimal","year":"2021","unstructured":"Barrera-Chimal J, Kolkhof P, Lima-Posada I, et al. Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists:head-to-head comparisons of pharmacological and clinical characteristics. Expert Opin Investig Drugs. 2021;30:1141\u201357. https:\/\/doi.org\/10.1080\/13543784.2021.2002844.","journal-title":"Expert Opin Investig Drugs"},{"key":"6619_CR8","doi-asserted-by":"publisher","DOI":"10.1159\/000548494","author":"DF M\u00e1rquez","year":"2025","unstructured":"M\u00e1rquez DF, Ortiz A, Gonz\u00e1lez-Moreno D, et al. Finerenone: evidence for benefit in early stages of cardiovascular-kidney-metabolic syndrome. Cardiorenal Med. 2025. https:\/\/doi.org\/10.1159\/000548494.","journal-title":"Cardiorenal Med"},{"key":"6619_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/164_2016_76","volume":"243","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, Jaisser F, Kim SY, et al. Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. Handb Exp Pharmacol. 2017;243:271\u2013305. https:\/\/doi.org\/10.1007\/164_2016_76.","journal-title":"Handb Exp Pharmacol"},{"key":"6619_CR10","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/cmdc.201200081","volume":"7","author":"L B\u00e4rfacker","year":"2012","unstructured":"B\u00e4rfacker L, Kuhl A, Hillisch A, et al. Discovery of BAY 94-8862:a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7:1385\u2013403. https:\/\/doi.org\/10.1002\/cmdc.201200081.","journal-title":"ChemMedChem"},{"key":"6619_CR11","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s13318-022-00770-z","volume":"47","author":"R Heinig","year":"2022","unstructured":"Heinig R, Nagelschmitz J, Loewen S. Results from phase I studies investigating the dose linearity of finerenone tablets and the influence of food or ph-modifying comedications on its pharmacokinetics in healthy male volunteers. Eur J Drug Metab Pharmacokinet. 2022;47:549\u201359. https:\/\/doi.org\/10.1007\/s13318-022-00770-z.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"6619_CR12","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391:1475\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2407107.","journal-title":"N Engl J Med"},{"key":"6619_CR13","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2025845.","journal-title":"N Engl J Med"},{"key":"6619_CR14","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenonein kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2110956.","journal-title":"N Engl J Med"},{"key":"6619_CR15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1161\/CIRCULATIONAHA.124.071452","volume":"151","author":"J Hu","year":"2025","unstructured":"Hu J, Zhou Q, Sun Y, et al. Efficacy and safety of finerenone in patients with primary aldosteronism:a pilot randomized controlled trial. Circulation. 2025;151:196\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.071452.","journal-title":"Circulation"},{"key":"6619_CR16","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/jch.14877","volume":"26","author":"CG Yu","year":"2024","unstructured":"Yu CG, Cao B, Gong HL, et al. Primary aldosteronism with postoperative elevation of aldosterone treated effectively by finerenone: a case report. J Clin Hypertens. 2024;26:1116\u201320. https:\/\/doi.org\/10.1111\/jch.14877.","journal-title":"J Clin Hypertens"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-06619-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06619-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06619-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:48:47Z","timestamp":1790855327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13256-026-06619-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6619"],"URL":"https:\/\/doi.org\/10.1186\/s13256-026-06619-2","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The studies involving human participants were reviewed and approved by the Ethics Committee of Jincheng People\u2019s Hospital. Ethics approval number: JCPH.No20260127002. The studies were conducted in accordance with local legislation and institutional requirements. Written informed consent to participate in this study was obtained from the participant. Written informed consent was also obtained from the participant for the publication of any potentially identifiable images or data included in this article.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report and any accompanying images. A copy of the written consent form is available for review by the editor of the journal. We confirmed that the privacy of the participants was preserved and that the data was anonymized and kept confidential.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"583"}}